CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01016977
NCT01016977Phase 4Completed
CompareCT.gov

A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris

Stiefel, a GSK Company·interventional·Posted Nov 20, 2009·Updated Jan 30, 2017

In Brief

A Phase 4 clinical trial evaluating Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene and clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene for Acne Vulgaris. Completed, enrolled 40 participants.

Detailed Summary

A single-blind (investigator-blinded), randomized, parallel group, single center study to evaluate the tolerability and efficacy of combination therapy with Duac Gel / 0.1% Tazorac Cream and Acanya Gel / 0.1% Tazorac Cream for the treatment of facial acne vulgaris.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
Countries--
CollaboratorsGlaxoSmithKline

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 20, 2009
Enrollment StartOct 1, 2009
Primary CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 16.6 years ago

Interventions

Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotenedrug

Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene

clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotenedrug

clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene